VBL Therapeutics Switches Tack After Pivotal Gene Therapy Ovarian Cancer Fail
Israeli Firm's Stock Sinks
The Israeli firm’s gene therapy asset has disappointed in an advanced ovarian cancer study, leaving experts skeptical of its potential in other tumors and the company turning to an earlier program.
